Results 191 to 200 of about 95,583 (387)

A monoclonal antibody against a Na(+)-L-glutamate cotransporter from rat brain

, 1992
B Hees, Niels C. Danbolt, Baruch I. Kanner, Winfried Haase, Karin Heitmann, Hermann Koepsell   +5 more
openalex   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source

Sodium/glucose cotransporter activity in cystic fibrosis. [PDF]

, 1996
P T Hardcastle, Chris Taylor
openalex   +1 more source

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists

ESC Heart Failure, EarlyView.
Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP‐1 RAs remain inadequately characterized.
Haoran Jiang, Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Erika Nicolsen, Todd McVeigh, Oksana Kamneva, Marat Fudim   +6 more
wiley   +1 more source

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials

Circulation, 2017
Y. Lytvyn, P. Bjornstad, J. Udell, J. Lovshin, D. Cherney   +4 more
semanticscholar   +1 more source

Molecular Cloning of a Novel Brain‐Type Na⁺‐Dependent Inorganic Phosphate Cotransporter [PDF]

, 2000
Yasuo Aihara, Hirosato Mashima, Hideaki Onda, Setsuji Hisano, Hidetoshi Kasuya, Tomokatsu Hori, Shirou Yamada, Hideaki Tomura, Yuichiro Yamada, Ituro Inoue, Itaru Kojima, Jun Takeda   +11 more
openalex   +1 more source

Do differences among heart failure patients affect their access to treatment?

ESC Heart Failure, EarlyView.
Halit Emre Yalvaç, Bulent Gorenek
wiley   +1 more source

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure (HF) is one of today's leading public health issues worldwide. The sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin recently received a label expansion. It is now approved for treatment of HF across the entire spectrum of ejection fraction (EF) in Germany. However, real‐world data are limited.
Matthias Paul, Ralph Bosch, Behrus Subin, Angelika Guth, Marlena Mueller, Mareike Seelinger, Stephanie Riemann, Birgit Assmus   +7 more
wiley   +1 more source